Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Ended
Participants planned
7
Countries
1
Sites
1
Vascular malformation
Key facts
- Sponsor
- Vaderis Therapeutics AG
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male
- Therapeutic area
- Diseases [C] - Cardiovascular Diseases [C14]
- Trial duration
- 31 Dec 2024 → 4 Mar 2025
- Decision date (initial)
- 2024-12-23
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Vascular malformation
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 20.1 | LLT | 10019887 | Hereditary hemorrhagic telangiectasia | 10010331 |
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Vaderis Therapeutics AG
- Sponsor organisation
- Vaderis Therapeutics AG
- Address
- Lichtstrasse 35
- City
- Basel
- Postcode
- 4056
- Country
- Switzerland
Scientific contact point
- Organisation
- Vaderis Therapeutics AG
- Contact name
- Damian Picard
Public contact point
- Organisation
- Vaderis Therapeutics AG
- Contact name
- Damian Picard
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Netherlands | Ended | 7 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Pharma Bio-Research Group
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Netherlands | 2024-12-31 | 2025-03-03 | 2025-01-06 | 2025-01-28 |
Application history
2 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2024-11-04 | Netherlands | Acceptable 2024-12-23
|
2024-12-23 |
| 2 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2024-12-31 | Netherlands | Acceptable 2024-12-23
|
2024-12-31 |